Literature DB >> 19537715

Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design.

David E Gloriam1, Steven M Foord, Frank E Blaney, Stephen L Garland.   

Abstract

Recent advances in structural biology for G-protein-coupled receptors (GPCRs) have provided new opportunities to improve the definition of the transmembrane binding pocket. Here a reference set of 44 residue positions accessible for ligand binding was defined through detailed analysis of all currently available crystal structures. This was used to characterize pharmacological relationships of Family A/Rhodopsin family GPCRs, minimizing evolutionary influence from parts of the receptor that do not generally affect ligand binding. The resultant dendogram tended to group receptors according to endogenous ligand types, although it revealed subdivision of certain classes, notably peptide and lipid receptors. The transmembrane binding site reference set, particularly when coupled with a means of identifying the subset of ligand binding residues, provides a general paradigm for understanding the pharmacology/selectivity profile of ligands at Family A GPCRs. This has wide applicability to GPCR drug design problems across many disease areas.

Mesh:

Substances:

Year:  2009        PMID: 19537715     DOI: 10.1021/jm900319e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  The G-protein-coupled receptor, GPR84, is important for eye development in Xenopus laevis.

Authors:  Kimberly J Perry; Verity R Johnson; Erica L Malloch; Lisa Fukui; Jason Wever; Alvin G Thomas; Paul W Hamilton; Jonathan J Henry
Journal:  Dev Dyn       Date:  2010-11       Impact factor: 3.780

Review 2.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Molecular dynamics simulations reveal specific interactions of post-translational palmitoyl modifications with rhodopsin in membranes.

Authors:  Bjoern E S Olausson; Alan Grossfield; Michael C Pitman; Michael F Brown; Scott E Feller; Alexander Vogel
Journal:  J Am Chem Soc       Date:  2012-02-22       Impact factor: 15.419

4.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

5.  A ligand's-eye view of protein similarity.

Authors:  Gerard J P van Westen; John P Overington
Journal:  Nat Methods       Date:  2013-02       Impact factor: 28.547

Review 6.  How Ligands Illuminate GPCR Molecular Pharmacology.

Authors:  Daniel Wacker; Raymond C Stevens; Bryan L Roth
Journal:  Cell       Date:  2017-07-27       Impact factor: 41.582

Review 7.  Integrating structural and mutagenesis data to elucidate GPCR ligand binding.

Authors:  Christian Munk; Kasper Harpsøe; Alexander S Hauser; Vignir Isberg; David E Gloriam
Journal:  Curr Opin Pharmacol       Date:  2016-07-29       Impact factor: 5.547

8.  Cross-pharmacology analysis of G protein-coupled receptors.

Authors:  Ferran Briansó; Maria C Carrascosa; Tudor I Oprea; Jordi Mestres
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

9.  A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization.

Authors:  Eelke van der Horst; Julio E Peironcely; Adriaan P Ijzerman; Margot W Beukers; Jonathan R Lane; Herman W T van Vlijmen; Michael T M Emmerich; Yasushi Okuno; Andreas Bender
Journal:  BMC Bioinformatics       Date:  2010-06-10       Impact factor: 3.169

10.  Activation induces structural changes in the liganded angiotensin II type 1 receptor.

Authors:  Martin Clément; Jérôme Cabana; Brian J Holleran; Richard Leduc; Gaétan Guillemette; Pierre Lavigne; Emanuel Escher
Journal:  J Biol Chem       Date:  2009-07-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.